BioSpace News Archive

Emergent BioSolutions Inc. announced selected preliminary unaudited 2019 financial results and its financial forecast for 2020.

Phase 2a study C-006 enrollment to be completed in 1Q 2020; data expected in 2Q 2020

Zynerba Pharmaceuticals, Inc., announced the achievement of its enrollment target for the 14-week Phase 2 BRIGHT trial of Zygel™ for the treatment of pediatric and adolescent patients with autism spectrum disorder.

Company Confirms Expectation of Topline Results in the Second Quarter of 2020

Replimune Group Inc., a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, provided a corporate update, highlighting the progress of its key programs.

Neovasc, Inc., a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, seeks to provide an update for investors, including a recap of recent corporate activity and a look ahead into 2020 in advance of the J.P. Morgan Investor Conference this week.

Amicus Therapeutics, a global, patient centric biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, provided its full-year 2020 strategic outlook and financial guidance.

Venus Concept Inc. announced preliminary unaudited revenue results for the three months and twelve months ended December 31, 2019 and introduced revenue guidance expectations for the twelve months ended December 31, 2020.

GenMark Diagnostics, Inc., a leading provider of automated, multiplex molecular diagnostic testing systems, provided preliminary operational and financial results for the year ended December 31, 2019.

Consolidated product sales totaled $7.0 M in the first quarter of 2020 compared with $6.8 M in the corresponding period in 2019, an increase of 3%;